An oral medication for a red blood cell dysfunction is approved as a consequence of phase 3 clinical trial findings

The outcomes of the randomised placebo-controlled ACTIVATE trial were released in the New England Journal of Medicine and were carried out by a global team that included researchers from Massachusetts General Hospital. The majority of people who have pyruvate kinase deficiency experience potentially fatal complications such iron overload in the liver and/or heart, osteoporosis, gallbladder […]

Scroll to top
Social media & sharing icons powered by UltimatelySocial

Enjoy this blog? Please spread the word :)